From: Calretinin as a blood-based biomarker for mesothelioma
Characteristics | Australia | Â | Germany | |||
---|---|---|---|---|---|---|
 | Group 1 | Group 2 | Group 3 | |||
 | Mesothelioma | Controls | Mesothelioma | Controls | Mesothelioma | Controls |
Total | 83 | 88 | 80 | 75 | 36 | 72 |
Histological subtype | ||||||
 Epithelioid | 27 (32.5%) |  | 48 (60.0%) |  | 28 (77.8%) |  |
 Sarcomatoid | 28 (33.7%) |  | 0 |  | 0 |  |
 Biphasic | 28 (33.7%) |  | 12 (15.0%) |  | 4 (11.1%) |  |
 Not specified | 0 |  | 20 (25.0%) |  | 4 (11.1%) |  |
Pathologic changes in controls | ||||||
 Plaques |  | 88 (100%) |  | 55 (73.3%) |  | 0 |
 Asbestosis |  | 0 |  | 0 |  | 44 (61.1%) |
 Asbestosis and plaques |  | 0 |  | 20 (26.7%) |  | 28 (38.9%) |
Year of blood drawing | 2005 | 2006 | 2012 | 2012 | 2011 | 2010 |
 Median (range) | (1996–2011) | (2000–2010) | (2011–2013) | (2011–2013) | (2008–2014) | (2009–2014) |
Age at blood drawing [years] | ||||||
 Median (range) | 70 (53–84) | 69.5 (52–84) | 70 (41–89) | 72 (53–90) | 70 (34–85) | 71 (43–83) |
Calretinin storage time [months] | ||||||
 Median (IQR) | 81.5 (42.9–111) | 59.8 (32.8–75.7) | 17.2 (7.4–23.2) | 19.3 (8.8–28.3) | 3.6 (1.9–7) | 10.9 (3.7–19.5) |
Mesothelin storage time [months] Median (IQR) | n.a. | n.a. | 21.3 (11.5–27.4) | 21.5 (11.1–30.4) | 7.5 (4.8–15.1) | 26.8 (19.1–31.9) |
Calretinin [ng/mL] | ||||||
 N < limit of detection | 30 (36.1%) | 61 (69.3%) | 20 (25.0%) | 73 (97.3%) | 12 (33.3%) | 62 (86.1%) |
 Median (IQR) | 0.79 (<0.28–1.70) | <0.19 (<0.09–0.63) | 1.10 (<0.48–2.16) | <0.01 (<0.01- < 0.08) | 1.01 (<0.33–1.74) | <0.20 (<0.08- < 0.34) |
 P-valuea | 0.0197 | <0.0001 | 0.0009 | |||
Mesothelin [nmol/L] | ||||||
 N < limit of detection | 0 | 0 | 1 (1.25%) | 14 (18.7%) | 0 | 0 |
 Median (IQR) | 2.65 (1.38–5.54) | 0.77 (0.53–1.08) | 4.06 (2.22–11.9) | 1.02 (0.46–1.45) | 2.01 (1.44–3.83) | 1.03 (0.73–1.21) |
 P-valueb | <0.0001 | <0.0001 | <0.0001 |